Case Study: Checkpoint Combination in Lung Cancer

Identify functional biomarkers of response in combination checkpoint therapies

Apply the single-cell functional proteomics to identify polyfunctional immune cell subsets which correlate with in vivo activity.

View the SC Polyfunctional Strength Solution

Research Area

Development Stage

Biomarkers

Goal

Identify functional biomarkers in combination checkpoint therapies

How our Award-Winning IsoLight Single-Cell System is Making a Difference

polyfunctional cell

Solution

PSI revealed differences in combination checkpoint therapy, identifying a potential biomarker of anti-tumor activity

polyfunctional cell

Finding

PSI predicts CPI patient response where other predictive biomarkers were inadequate

follow our data

Follow Our Data

See the latest published data in Checkpoint & Combination Immunotherapies

Current predictive biomarkers such as PD-L1 expression, TMB, MSI have potentially been inadequate.1

Polyfunctional Strength Index (PSI) is a potential predictive biomarker of CPI response, linking single-cell cytokine profiling to clinical outcome, especially in a MET-amplified lung adenocarcinoma.2

View the SC Polyfunctional Strength Solution
  1. Yi M et al., Mol Cancer. 2018; 17: 129
  2. Lim et al. TRCCC 2019
cd4-cd8lung-sections

Request a Seminar

Request a Seminar
Discover IsoLight